. Author manuscript; available in PMC: 2016 Nov 1.

Published in final edited form as: Am J Med. 2015 Jul 11;128(11):1252.e1–1252.e11. doi: 10.1016/j.amjmed.2015.06.030

Table 3.

Adverse Outcomes Over One Year: Statin initiators compared to statin non-initiators, overall and by level of kidney function. Hazard ratios and 95% confidence intervals were estimated from Cox proportional hazards regression

	Statin Initators (n=5,597; 4,504 without diabetes at baseline)		Statin Non-initiators (n=5,583; 4,510 without diabetes at baseline)		PS Matched and Adjusted Hazard Ratio (95% CI)

	Events	Events per 100 person years	Events	Events per 100 person years
Diabetes^*	447	11.52	400	10.71	0.97 (0.84, 1.12)
P-value for interaction of statin initiation by level of kidney function					0.58
Myopathy	54	1.34	66	1.04	0.82 (0.57, 1.20)
P-value for interaction of statin initiation by level of kidney function					0.98

among patients without diabetes at baseline